Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results

Neoadjuvant chemotherapy (NA) is routinely offered to patients undergoing resection for locally advanced (≥cT3Nx or cTxN+) esophageal or esophagogastric junctional (EGJ) cancer in the United Kingdom. Patients with comorbidity precluding the use of NA can be considered for resection yet the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Neill, J. Robert, Kennedy, Ewan D., Save, Vicki, Langdale-Brown, Barbara, Wall, Lucy, Skipworth, Richard J.E., Paterson-Brown, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2017
Materias:
Cohort Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673116/
https://www.ncbi.nlm.nih.gov/pubmed/29177210
http://dx.doi.org/10.1097/IJ9.0000000000000009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673116/
https://www.ncbi.nlm.nih.gov/pubmed/29177210
http://dx.doi.org/10.1097/IJ9.0000000000000009

Ejemplares similares